Published in Bone Marrow Transplant on October 01, 1993
Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. J Exp Med (1995) 4.57
Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine (2000) 3.22
Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax (2004) 2.45
Meeting the challenge of prescribing and administering medicines safely: structured teaching and assessment for final year medical students. Med Educ (2003) 2.33
Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess (2007) 2.23
Mesangial IgA1 in IgA nephropathy exhibits aberrant O-glycosylation: observations in three patients. Kidney Int (2001) 1.99
Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria. J Infect Dis (1992) 1.98
The chlamydia screening studies: rationale and design. Sex Transm Infect (2004) 1.83
Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. Immunology (1994) 1.81
Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum (1993) 1.79
Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med (1994) 1.64
Sequential development of systemic vasculitis with anti-neutrophil cytoplasmic antibodies complicating anti-glomerular basement membrane disease. Clin Nephrol (1989) 1.63
T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol (1994) 1.62
Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity. J Biol Chem (1991) 1.57
Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med (1997) 1.50
Interleukin-6: a sensitive parameter for the early diagnosis of neonatal bacterial infection. Pediatrics (1994) 1.49
Vascular endothelial growth factor (VEGF) is released from platelets during blood clotting: implications for measurement of circulating VEGF levels in clinical disease. Clin Sci (Lond) (1998) 1.46
Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant (1993) 1.43
Screening to prevent spontaneous preterm birth: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess (2009) 1.43
Cost-effectiveness of rapid tests and other existing strategies for screening and management of early-onset group B streptococcus during labour. BJOG (2010) 1.41
Therapy-related acute promyelocytic leukaemia. Br J Haematol (1994) 1.39
Pulse oximetry as a screening test for congenital heart defects in newborn infants: a test accuracy study with evaluation of acceptability and cost-effectiveness. Health Technol Assess (2012) 1.38
Rhabdomyosarcoma presenting as 'acute leukaemia'. Histopathology (1991) 1.38
Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis (1994) 1.37
Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess (2008) 1.37
Predominance of Th1-type T cells in synovial fluid of patients with Yersinia-induced reactive arthritis. Eur J Immunol (1992) 1.36
Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechçet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol (1997) 1.29
Evaluation of a test system for measuring cytokine production in human whole blood cell cultures. J Immunol Methods (1991) 1.28
Antenatal screening for haemoglobinopathies in primary care: a cohort study and cluster randomised trial to inform a simulation model. The Screening for Haemoglobinopathies in First Trimester (SHIFT) trial. Health Technol Assess (2010) 1.26
Patterns of proinflammatory cytokines and inhibitors during typhoid fever. J Infect Dis (1994) 1.23
Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia (1996) 1.21
[Horseradish peroxidase: kinetic studies and optimization of peroxidase activity determination using the substrates H2O2 and 3,3',5,5'-tetramethylbenzidine]. J Clin Chem Clin Biochem (1985) 1.20
Relapsed myelodysplastic clone differs from acute onset clone as shown by X-linked DNA polymorphism patterns in a patient with acute myeloid leukemia. Blood (1993) 1.20
Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin Exp Immunol (2000) 1.16
Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology (1992) 1.16
Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology (2001) 1.15
Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-alpha (TNF-alpha) in synovial fluid. Clin Exp Immunol (1999) 1.14
Evaluation of interleukin-6 and soluble receptors of tumor necrosis factor for early diagnosis of neonatal infection. J Pediatr (1996) 1.13
Antiviral screening of British Columbian medicinal plants. J Ethnopharmacol (1995) 1.12
Pattern of soluble TNF receptors I and II in sepsis. Infection (1996) 1.10
Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine (1998) 1.10
Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol (1995) 1.10
Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum (1993) 1.08
Antigen-presenting human T cells and antigen-presenting B cells induce a similar cytokine profile in specific T cell clones. Eur J Immunol (1993) 1.08
Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr (1994) 1.07
Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis (1993) 1.05
Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology (1995) 1.05
Glomerular basement membrane proteoglycans are derived from a large precursor. J Cell Biol (1988) 1.04
Different pattern of local and systemic release of proinflammatory and anti-inflammatory mediators in severely injured patients with chest trauma. J Trauma (1996) 1.04
Release of anti-inflammatory mediators after mechanical trauma correlates with severity of injury and clinical outcome. J Trauma (1995) 1.02
Interleukin-6, gamma interferon, and tumor necrosis factor receptors in typhoid fever related to outcome of antimicrobial therapy. Antimicrob Agents Chemother (1993) 1.01
Abnormal synthesis of 1,25-dihydroxyvitamin D in patients with malignant lymphoma. J Clin Endocrinol Metab (1994) 1.01
Complete recovery of histiocytic medullary reticulosis-like syndrome in a child with acute lymphoblastic leukemia. Cancer (1983) 0.98
Sequential study of the IgA system in relapsing IgA nephropathy. Kidney Int (1986) 0.98
Modulation of cellular immune function by cyclophosphamide in children with minimal-change nephropathy. N Engl J Med (1984) 0.98
Adult respiratory distress syndrome - an update. Histopathology (1999) 0.98
Cellular expression of tumour necrosis factor-alpha and interferon-gamma in the liver biopsies of children with chronic liver disease. J Hepatol (1994) 0.97
Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation. J Clin Pathol (1999) 0.95
[Enzyme-immunological tests: determination of the activity of peroxidase with the aid of the "Trinder reagent" (author's transl)]. J Clin Chem Clin Biochem (1977) 0.95
Tumor necrosis factor alpha and soluble tumor necrosis factor receptors in individuals with human immunodeficiency virus infection. Immunol Lett (1994) 0.95
Analysis of the in vitro cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis. Clin Exp Immunol (1993) 0.94
Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis. Virchows Arch (1997) 0.94
Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts. Eur J Immunol (1995) 0.94
Ultrasonography for rheumatologists: the development of specific competency based educational outcomes. Ann Rheum Dis (2005) 0.94
Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J Immunol (1996) 0.94
Mast cells: the forgotten cells of renal fibrosis. J Clin Pathol (2000) 0.94
Differential effects of IL-10 on proliferation and cytokine production of human gamma/delta and alpha/beta T cells. Scand J Immunol (1994) 0.94
The molecular biology of infectious pancreatic necrosis virus: a review. Can J Microbiol (1983) 0.93
Exogenous glutamine requirement is confined to late events of T cell activation. J Cell Biochem (1993) 0.93
Identity between human interferon-gamma and "macrophage-activating factor" produced by human T lymphocytes. Eur J Immunol (1986) 0.93
Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. Br J Haematol (2001) 0.92
[Interferon: A greatly simplified immuno enzyme determination with two monoclonal antibodies]. J Clin Chem Clin Biochem (1982) 0.92
Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr (1994) 0.92
High concentrations of soluble tumor necrosis factor receptors in ascites. Hepatology (1992) 0.92
Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol (1993) 0.92
Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy. Kidney Int (1995) 0.91
Cytokine levels in whole blood cell cultures as parameters of the cellular immunologic activity in patients with malignant melanoma and basal cell carcinoma. Cancer (1993) 0.91
Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder, renal cell and prostate carcinomas. Tumour Biol (1998) 0.91
An association between antibodies specific for endothelial cells and renal transplant failure. Transpl Immunol (1998) 0.90
Achieving pregnancy against the odds: successful implantation of frozen-thawed embryos generated by ICSI using spermatozoa banked prior to chemo/radiotherapy for Hodgkin's disease and acute leukaemia. Hum Reprod (2001) 0.90
Increased release of soluble tumor necrosis factor receptors into blood during clinical sepsis. Arch Surg (1994) 0.89
The Percutaneous shunting in Lower Urinary Tract Obstruction (PLUTO) study and randomised controlled trial: evaluation of the effectiveness, cost-effectiveness and acceptability of percutaneous vesicoamniotic shunting for lower urinary tract obstruction. Health Technol Assess (2013) 0.89
Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol (1998) 0.89
Evaluating the utility of workplace-based assessment tools for speciality training. Best Pract Res Clin Obstet Gynaecol (2010) 0.88
[Horseradish peroxidase: a study of the kinetics and the determination of optimal reaction conditions, using hydrogen peroxide and 2,2'-azinobis 3-ethylbenzthiazoline-6-sulfonic acid (ABTS) as substrates (author's transl)]. J Clin Chem Clin Biochem (1979) 0.88
Psoriasis and bone marrow transplantation. BMJ (1990) 0.88
Serum levels and in situ expression of TNF-alpha and TNF-alpha binding proteins in inflammatory liver diseases. Cytokine (1996) 0.88
A genetic marker of high TNF-alpha production in heart transplant recipients. Transplantation (1995) 0.88
Plasma TGF beta in systemic sclerosis: a cross-sectional study. Ann Rheum Dis (1994) 0.88
Perceptions of professionalism in medicine: a qualitative study. Med Educ (2006) 0.88
The development of an evidence-based educational framework to facilitate the training of competent rheumatologist ultrasonographers. Rheumatology (Oxford) (2007) 0.87
Stimulation of autologous proliferative and cytotoxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia. Blood (2001) 0.87
Increased basal ganglia iron in striatonigral degeneration: in vivo estimation with magnetic resonance. Can J Neurol Sci (1998) 0.86
A peroxidase-linked enzyme immunoassay for tumour necrosis factor alpha utilising alternative colorimetric or chemilumimetric substrates. J Immunol Methods (1992) 0.86
Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate. J Rheumatol (1996) 0.86
Cytokine production in whole blood cell cultures of patients with Crohn's disease and ulcerative colitis. J Clin Lab Anal (1994) 0.86
Cytokine production in leukocyte cultures during therapy with Echinacea extract. J Clin Lab Anal (1996) 0.86
Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody. J Clin Immunol (1995) 0.85